| 10/13/2026 7:00 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/13/2026 7:05 AM | Conduit Pharmaceuticals (1896212) Filer | Form 424B3 | |
| 10/08/2026 3:05 PM | Conduit Pharmaceuticals (1896212) Subject Primary Development Fund (0) Cayman | Form SCHEDULE 13G/A | |
| 10/07/2026 3:05 PM | Conduit Pharmaceuticals (1896212) Subject Wigglesworth Craig Stuart (2154266) Filed by | Form SCHEDULE 13G/A | |
| 10/07/2026 3:05 PM | Conduit Pharmaceuticals (1896212) Subject Taylor Mark Andrew (2119432) Filed by | Form SCHEDULE 13G/A | |
| 10/07/2026 3:06 PM | Conduit Pharmaceuticals (1896212) Subject Primary Development Fund (0) Cayman | Form SCHEDULE 13G | |
| 10/02/2026 7:35 AM | Conduit Pharmaceuticals (1896212) Filer | Form 424B3 | |
| 09/25/2026 7:15 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/18/2026 4:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/18/2026 4:20 PM | Conduit Pharmaceuticals (1896212) Filer | Form 424B3 | |
| 09/18/2026 3:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form 424B3 | |
Get the Latest News and Ratings for CDTTW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/17/2026 11:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form EFFECT | |
| 09/09/2026 5:09 PM | Conduit Pharmaceuticals (1896212) Subject Wigglesworth Craig Stuart (2154266) Filed by | Form SCHEDULE 13G | |
| 09/08/2026 4:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form S-1 Registration statement under Securities Act of 1933 | |
| 09/04/2026 3:05 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/02/2026 5:10 PM | Conduit Pharmaceuticals (1896212) Subject Corvus Capital Ltd. (1990829) Filed by | Form SCHEDULE 13D/A | |
| 09/02/2026 5:12 PM | Conduit Pharmaceuticals (1896212) Issuer Regan Andrew (1991325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/02/2026 5:16 PM | Conduit Pharmaceuticals (1896212) Subject Taylor Mark Andrew (2119432) Filed by | Form SCHEDULE 13G | |
| 09/01/2026 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/01/2026 7:00 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/21/2026 4:26 PM | Conduit Pharmaceuticals (1896212) Subject Primary Development Fund (0) Cayman | Form SCHEDULE 13G | |
| 08/21/2026 4:29 PM | Conduit Pharmaceuticals (1896212) Subject Primary Development Fund (0) Cayman | Form SCHEDULE 13G | |
| 08/21/2026 8:27 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K/A | |
| 08/21/2026 8:27 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K/A | |
| 08/12/2026 4:29 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/12/2026 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form DEFA14A | |
| 08/11/2026 7:45 AM | Conduit Pharmaceuticals (1896212) Filer | Form DEF 14A | |
| 08/11/2026 7:49 AM | Conduit Pharmaceuticals (1896212) Filer | Form ARS | |
| 07/31/2026 4:26 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/31/2026 4:29 PM | Conduit Pharmaceuticals (1896212) Filer | Form PRE 14A | |
| 07/16/2026 7:05 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/15/2026 3:46 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/07/2026 4:20 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/29/2026 3:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/23/2026 5:40 PM | Conduit Pharmaceuticals (1896212) Issuer Prospect Capital Securities Ltd (2120744) Reporting Prospect Finance Ltd (2120961) Reporting Taylor Mark Andrew (2119432) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/23/2026 5:42 PM | Conduit Pharmaceuticals (1896212) Subject Taylor Mark Andrew (2119432) Filed by | Form SCHEDULE 13D/A | |
| 06/16/2026 4:00 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/05/2026 7:51 PM | Ascent Partners Fund LLC (2059960) Filed by Conduit Pharmaceuticals (1896212) Subject | Form SCHEDULE 13G | |
| 05/20/2026 6:03 PM | Conduit Pharmaceuticals (1896212) Subject Nirland Ltd (1994188) Filed by | Form SCHEDULE 13G | |
| 05/14/2026 7:42 AM | Conduit Pharmaceuticals (1896212) Issuer Regan Andrew (1991325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 7:47 AM | Conduit Pharmaceuticals (1896212) Subject Corvus Capital Ltd. (1990829) Filed by | Form SCHEDULE 13D/A | |
Trump’s issues shocking Executive Order on U.S. Dollar (Ad) Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered.
Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18.
Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system. Read the full breakdown of Executive Order 14178 now |
| 05/03/2026 11:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form EFFECT | |
| 05/01/2026 4:11 PM | Conduit Pharmaceuticals (1896212) Filer | Form 424B3 | |
| 04/30/2026 7:16 PM | Conduit Pharmaceuticals (1896212) Issuer Olsen Ulrik K (2132215) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 04/21/2026 8:56 PM | Conduit Pharmaceuticals (1896212) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 04/15/2026 4:01 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/30/2026 8:21 PM | Conduit Pharmaceuticals (1896212) Subject Taylor Mark Andrew (2119432) Filed by | Form SCHEDULE 13D | |
| 03/30/2026 8:22 PM | Conduit Pharmaceuticals (1896212) Issuer Prospect Capital Securities Ltd (2120744) Reporting Prospect Finance Ltd (2120961) Reporting Taylor Mark Andrew (2119432) Reporting Taylor Mark Andrew (2119432) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/30/2026 8:23 PM | Conduit Pharmaceuticals (1896212) Issuer Prospect Capital Securities Ltd (2120744) Reporting Prospect Capital Securities Ltd (2120744) Reporting Prospect Finance Ltd (2120961) Reporting Taylor Mark Andrew (2119432) Reporting Taylor Mark Andrew (2119432) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/25/2026 7:15 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/18/2026 3:53 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/06/2026 3:12 PM | Conduit Pharmaceuticals (1896212) Filer | Form DEF 14A | |
| 02/24/2026 3:53 PM | Conduit Pharmaceuticals (1896212) Filer | Form PRE 14A | |
| 02/23/2026 7:27 PM | Conduit Pharmaceuticals (1896212) Issuer Farley Chele Chiavacci (1908750) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/18/2026 5:26 PM | Ascent Partners Fund LLC (2059960) Filed by Conduit Pharmaceuticals (1896212) Subject | Form SCHEDULE 13G | |
| 02/09/2026 11:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form EFFECT | |
| 01/30/2026 8:06 AM | Conduit Pharmaceuticals (1896212) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 01/22/2026 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/02/2026 3:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/22/2025 3:05 PM | Conduit Pharmaceuticals (1896212) Subject Corvus Capital Ltd. (1990829) Filed by | Form SCHEDULE 13D/A | |
| 12/22/2025 3:05 PM | Conduit Pharmaceuticals (1896212) Issuer Corvus Capital Ltd. (1990829) Reporting Regan Andrew (1991325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/13/2025 3:46 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |